Haptoglobin 1-1 and Low Protein Levels: Identifying the Lowest Cardiovascular Risk in Type 2 Diabetes
Posted inCardiology Diabetes & Endocrinology news

Haptoglobin 1-1 and Low Protein Levels: Identifying the Lowest Cardiovascular Risk in Type 2 Diabetes

A FIELD sub-study reveals that while higher haptoglobin levels increase cardiovascular risk—particularly in those with the HP 1-1 phenotype—fenofibrate's protective effects remain consistent regardless of haptoglobin status, challenging previous assumptions about phenotype-specific treatment responses.
School-Based Interventions Achieve Dramatic Reduction in Ultra-Processed Food Consumption Among Indian Adolescents
Posted innews Pediatrics Public Health

School-Based Interventions Achieve Dramatic Reduction in Ultra-Processed Food Consumption Among Indian Adolescents

A cluster-randomised trial in India demonstrates that a 6-month school-based behavioural intervention significantly reduces ultra-processed food consumption among adolescents by over 1000 Kcal/day, highlighting a scalable strategy to combat the rising burden of diet-related non-communicable diseases in low- and middle-income countries.
Substituting Water for Artificially Sweetened Beverages Fails to Improve Glycemic Control in Type 2 Diabetes: Results from the SODAS Trial
Posted inDiabetes & Endocrinology Internal Medicine news

Substituting Water for Artificially Sweetened Beverages Fails to Improve Glycemic Control in Type 2 Diabetes: Results from the SODAS Trial

The Study of Drinks with Artificial Sweeteners (SODAS) randomized trial reveals that replacing habitual artificially sweetened beverages with water does not improve HbA1c levels in patients with type 2 diabetes, with the water group surprisingly showing higher HbA1c levels than the beverage group.
Oral Semaglutide Slows eGFR Decline in Patients with Type 2 Diabetes and High Cardiovascular Risk: Insights from the SOUL Trial
Posted inCardiology Diabetes & Endocrinology Nephrology news

Oral Semaglutide Slows eGFR Decline in Patients with Type 2 Diabetes and High Cardiovascular Risk: Insights from the SOUL Trial

The SOUL trial demonstrates that oral semaglutide significantly slows the annual decline of estimated glomerular filtration rate (eGFR) in patients with type 2 diabetes and cardiovascular disease, despite not meeting the primary composite kidney endpoint in a population with preserved baseline renal function.
Tau Pathology Acts as a Switch: How Soluble Amyloid Drives Early Metabolic and Neuropsychiatric Symptoms in Alzheimer’s Disease
Posted inNeurology news Psychiatry

Tau Pathology Acts as a Switch: How Soluble Amyloid Drives Early Metabolic and Neuropsychiatric Symptoms in Alzheimer’s Disease

Recent clinical evidence reveals that soluble amyloid-beta oligomers, rather than traditional plaques, drive glucose dysregulation and depression in early Alzheimer’s disease. Crucially, these associations are modulated by tau pathology, suggesting that tau staging is essential for identifying metabolic and psychiatric vulnerability in the AD spectrum.